Last reviewed · How we verify
Micronised Progesterone
At a glance
| Generic name | Micronised Progesterone |
|---|---|
| Also known as | Crinone 8% |
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Comparison Between Vaginal Pessary and Progestogen in Twin Pregnancy With Short Cervical Length (PHASE3)
- Comparison of Dydrogesterone and Micronized Progesterone Treatments in the Treatment of Threatened Miscarriage. (PHASE4)
- The Effect of Different Types of Progestin on Sleeping of Menopausal Women (NA)
- Randomized Controlled Trial of Vaginal Progesterone in Women With Threatened Preterm Labor (PHASE4)
- A Study Using Micronised Progesterone (Crinone® 8%) in the Luteal Phase Support of Women Undergoing in Vitro Fertilisation (IVF) and Embryo Transfer (ET) (PHASE3)
- Progesterone for Prevention of Preterm Birth in Women With Short Cervix: Randomized Controlled Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Micronised Progesterone CI brief — competitive landscape report
- Micronised Progesterone updates RSS · CI watch RSS
- Merck KGaA, Darmstadt, Germany portfolio CI